In the early 1980s the discovery and isolation of a new because changes in pulmonary resistance induced by PAF were rather small and larger degrees of bronchoconstriction lipid mediator, platelet activating factor (PAF), led to a lot of activity and excitement in the inflammation world.
A 2 and acetyltransferase on membrane alkylacyl phospholipids. PAF was found to possess many properties that made it well suited as a proinflammatory mediator of inflammation in many inflammatory diseases. 1 Interest in Degradation of PAF its potential role as a mediator of asthma was fuelled Being a potent bioactive mediator, it makes sense that PAF by the observations that it induced airway microvascular can be degraded rapidly by PAF acetylhydrolase which leakage, bronchconstriction, and bronchial hyperwould therefore limit the activity of PAF. A decrease in PAF responsiveness. In addition, PAF could activate a wide acetylhydrolase activity would lead to greater inflammatory variety of cells including neutrophils, eosinophils, and responses induced by endogenously released PAF. Recent endothelial cells, and was also found to have potent chemostudies in Japan have examined the presence of respiratory attractant properties for eosinophils. With the discovery of symptoms in asthmatic children and the activity of serum PAF receptor antagonists, the hypothesis that PAF was PAF acetylhydrolase. 9 These investigators found that 4% involved in chronic asthma was tested. In two studies of of a healthy Japanese population had a deficiency of this moderate to severe asthmatic patients no positive clinical enzyme and that, amongst asthmatic children, the severity benefit was demonstrated with two different PAF receptor of symptoms was greater in those with PAF acetylhydrolase antagonists, 2 3 casting doubt on the contribution of PAF to deficiency. More recently, the inherited serum PAF acetylthe pathophysiology of chronic asthma despite the fact that hydrolase deficiency was found to be the result of a point PAF or its metabolite or precursor, lyso-PAF, is released mutation in exon 9 which leads to complete abolition of in the airways of patients with asthma. It has been argued enzymatic activity. 10 Whether these individuals are more that the potency of the receptor antagonists may not have prone to inflammatory conditions such as asthma can only been adequate in the in vivo situation, or these antagonists be determined by prospective studies. Perhaps of more may not be blocking the effects of other bioactive PAF relevance is whether this deficiency could lead to more homologues acting perhaps at different PAF receptor subsevere asthma in asthmatic patients. types. A preliminary study performed in Japan indicated that a higher dose of one of the two antagonists used, WEB 2086, provided some benefit in steroid-dependent asthmatic patients. 4 However, enthusiasm for studying PAF Proinflammatory effects of PAF antagonists in asthma has waned. Despite this, further
The study by Shindo and colleagues further extends the interesting observations continue to be reported, parwell known proinflammatory effects of PAF. They have ticularly with relation to its potential role in asthma, infound that PAF can prime neutrophils from asthmatic cluding the paper published by Shindo et al in this issue
patients, but not from normal volunteers, to release more of Thorax. 5 products of 5-lipoxygenase (5-LO) -namely LTB 4 and 5-HETE -when these cells are activated by calcium ionophore. Shindo et al propose that this priming effect on 5-LO activity is secondary to the enhancement of calcium PAF and ventilation-perfusion distribution Rodriguez-Roisin and colleagues have recently extended influx by PAF, but there were no differences in PAFinduced production of LTB 4 between normal and asthmatic the effects of PAF in man by studying its actions on pulmonary gas exchange.
6 7 In both normal and asthmatic neutrophils. It is of interest that preincubation of neutrophils with granulocyte-macrophage colony-stimulating facsubjects inhaled PAF induced small falls in arterial P 2 with more profound changes in arterial-alveolar P 2 that tor (GM-CSF) can enhance the ability of PAF to stimulate leukotriene synthesis by increasing both arachidonic acid were entirely caused by ventilation-perfusion (V/Q) mismatch. The pattern of V/Q mismatch was similar to that availability and 5-lipoxygenase activity. 11 Thus, a priming effect of GM-CSF on neutrophils which in turn primes commonly found in patients with acute severe asthma, which has led to the hypothesis that PAF could underlie the effects of PAF is plausible and would represent a real cascade effect on the final neutrophil response. IgEthe hypoxaemia seen in this condition. Acute severe asthma is also characterised by intense oedema and mucus plugging dependent release of LTC 4 and histamine from human basophils is also enhanced by PAF after preincubation with which could be initiated by PAF. PAF-induced ventilationperfusion mismatch was not related to airway constriction GM-CSF. 12 Shindo et al have also previously shown that group.bmj.com on June 25, 2017 -Published by http://thorax.bmj.com/ Downloaded from
